Zimmer Biomet (ZBH) signed a definitive agreement to acquire Monogram Technologies (MGRM) for a cash payment of $4.04 per common share, for a total equity value of about $177 million, the companies said Monday.
Shares of Monogram soared 76% as intraday trading volume catapulted to over 13.4 million from a daily average of about 60,000.
Dare Bioscience (DARE) said Monday that interim results from its phase 3 clinical trial showed that its investigational monthly, hormone-free intravaginal contraceptive, Ovaprene, met the company's expectations.
Shares surged 66% as intraday trading volume climbed to more than 63.8 million from a daily average of about 163,000.
Sonnet BioTherapeutics (SONN) shares soared 72% amid heavy trading after the company said it agreed to merge with Rorschach, backed by Atlas Merchant Capital and Paradigm Operations, and will build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.
More than 40.2 million shares of Sonnet traded intraday compared with a daily average of about 2.91 million.
Price: 93.61, Change: -0.19, Percent Change: -0.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.